We also tested the effects of AAV GBA1 delivery on α-synuclein pathology in PD models in vitro using mouse primary neurons treated with mouse α-synuclein pre-formed fibrils (PFFs) and in vivo, in the CBE-chemically induced A53T M83 mouse model. This evidence concerns the gene GBA1 and Parkinson disease.